2023 ASCO Highlights Webinar-2023 ASCO Highlights Webinar

Video Transcription

Video Summary

In this webinar, three important abstracts from ASCO 2023 were discussed. The first abstract focused on the perioperative use of pembrolizumab in early-stage non-small cell lung cancer. The randomized phase III trial showed that adding pembrolizumab to chemotherapy before and after surgery improved event-free survival compared to chemotherapy alone. The trial also found that patients with high PD-L1 expression, greater than 50%, and those with higher stage disease had the most significant benefit from the perioperative pembrolizumab. The second abstract presented the results of the Adora trial, which investigated the use of adjuvant osmirtenib in resected EGFR-mutated non-small cell lung cancer. The trial found that adjuvant osmirtenib significantly improved disease-free survival and showed a trend towards improved overall survival compared to placebo. However, the optimal duration of adjuvant osmirtenib and the cumulative toxicities of long-term treatment still need to be investigated. The third abstract discussed the use of pembrolizumab in EGFR-mutated non-small cell lung cancer that has become resistant to EGFR tyrosine kinase inhibitors. The trial found that adding pembrolizumab to chemotherapy did not significantly improve progression-free survival or overall survival compared to placebo. The study also highlighted the limited efficacy of immune checkpoint inhibitors in the EGFR-mutated population. Overall, the webinar provided important insights into the use of immunotherapies in different stages and settings of non-small cell lung cancer.

Keywords

webinar

ASCO 2023

pembrolizumab

non-small cell lung cancer

chemotherapy

adjuvant osmirtenib

EGFR-mutated

disease-free survival

immune checkpoint inhibitors